EA202090108A1 - Применение церебролизина - Google Patents

Применение церебролизина

Info

Publication number
EA202090108A1
EA202090108A1 EA202090108A EA202090108A EA202090108A1 EA 202090108 A1 EA202090108 A1 EA 202090108A1 EA 202090108 A EA202090108 A EA 202090108A EA 202090108 A EA202090108 A EA 202090108A EA 202090108 A1 EA202090108 A1 EA 202090108A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cerebrolysine
application
cerebrolysin
cadasil
leukoencephalopathy
Prior art date
Application number
EA202090108A
Other languages
English (en)
Russian (ru)
Inventor
Штефан Винтер
Херберт Мёсслер
Original Assignee
Эвер Нейро Фарма Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эвер Нейро Фарма Гмбх filed Critical Эвер Нейро Фарма Гмбх
Publication of EA202090108A1 publication Critical patent/EA202090108A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
EA202090108A 2017-08-28 2018-08-28 Применение церебролизина EA202090108A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17188180.8A EP3449931B1 (en) 2017-08-28 2017-08-28 Use of cerebrolysin
PCT/EP2018/073106 WO2019042983A1 (en) 2017-08-28 2018-08-28 USE OF CERBROLYSINE

Publications (1)

Publication Number Publication Date
EA202090108A1 true EA202090108A1 (ru) 2020-03-31

Family

ID=59745228

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090108A EA202090108A1 (ru) 2017-08-28 2018-08-28 Применение церебролизина

Country Status (15)

Country Link
US (1) US12589118B2 (https=)
EP (2) EP3449931B1 (https=)
JP (1) JP7281450B2 (https=)
KR (1) KR102676274B1 (https=)
CN (1) CN111050780B (https=)
AU (1) AU2018326339A1 (https=)
CA (1) CA3073991A1 (https=)
EA (1) EA202090108A1 (https=)
ES (2) ES2767070T3 (https=)
HR (1) HRP20200031T1 (https=)
MX (1) MX2020002267A (https=)
PH (1) PH12020500376A1 (https=)
PL (2) PL3449931T3 (https=)
UA (1) UA129400C2 (https=)
WO (1) WO2019042983A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020198037A1 (en) * 2019-03-25 2020-10-01 The University Of Vermont Methods to promote cerebral blood flow in the brain
WO2022013236A1 (en) 2020-07-13 2022-01-20 Ever Neuro Pharma Gmbh Method for producing a mammalian brain protein hydrolysate
IL307903A (en) * 2021-06-02 2023-12-01 Regeneron Pharma Treatment of cerebrovascular disease with Notts homolog protein factors 3 neurogenic locus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69126563T2 (de) 1990-04-12 1998-02-05 Ebewe Arzneimittel Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia
EP1857463A1 (en) * 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
EP2334287A4 (en) 2008-08-20 2013-12-25 Univ Texas MELT EXTRUSION OF MULTIPARTICLES WITH MODIFIED RELEASE

Also Published As

Publication number Publication date
PL3449931T3 (pl) 2020-06-01
KR20200045503A (ko) 2020-05-04
CN111050780B (zh) 2023-11-03
PL3675879T3 (pl) 2022-02-14
JP2020531568A (ja) 2020-11-05
UA129400C2 (uk) 2025-04-16
HRP20200031T1 (hr) 2020-03-20
KR102676274B1 (ko) 2024-06-18
ES2901508T3 (es) 2022-03-22
PH12020500376A1 (en) 2020-12-07
US20200376040A1 (en) 2020-12-03
JP7281450B2 (ja) 2023-05-25
CA3073991A1 (en) 2019-03-07
EP3675879B1 (en) 2021-09-15
AU2018326339A1 (en) 2020-03-05
EP3449931A1 (en) 2019-03-06
ES2767070T3 (es) 2020-06-16
EP3675879A1 (en) 2020-07-08
CN111050780A (zh) 2020-04-21
EP3449931B1 (en) 2019-10-16
MX2020002267A (es) 2020-10-22
WO2019042983A1 (en) 2019-03-07
US12589118B2 (en) 2026-03-31

Similar Documents

Publication Publication Date Title
EA201691607A1 (ru) Микроорганоиды и способы их получения и применения
EA202090655A1 (ru) Комбинированные терапевтические средства и их применение
EA202091865A1 (ru) Композиции и способы для снижения экспрессии tau
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX2017003627A (es) Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
EA201791866A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA201790737A1 (ru) Комбинированная терапия
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
MX377712B (es) Anticuerpos dirigidos contra il-33 y sus usos.
EA201692316A1 (ru) Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний
EA201690456A1 (ru) Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201491721A1 (ru) Соединения и способы модуляции киназ и показания для их применения
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
EP3337805A4 (en) INHIBITORS OF THE TEC KINASE ENZYM FAMILY
EA201690559A1 (ru) Способы определения ответа на терапию
EA201792281A1 (ru) Твердые формы 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4- метилциклогексиламино)пиримидин-5-карбоксамида, его композиции и способы его применения